[Changes of blood antioxidative enzyme activity and lipid levels in patients with coronary atherosclerosis treated with probucol].
The paper provides the results of 3-month probucol (lipomal) treatment of patients with coronary heart disease concurrent with Types 2a and 2b hyperlipidemia. There were 20% and 17% decreases in total cholesterol and low density lipoprotein cholesterol levels, respectively. The drug failed to affect the levels of high density lipoprotein cholesterol and triglycerides. Having antioxidative properties, probucol significantly enhances the activity of the antioxidative enzymes superoxide dismutase and glutathione peroxidase, which controls the efficacy of coronary heart disease patients with hyperlipidemia.